DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Surface N-Glycosylation Dictates MSC-EV Uptake and CCR2-Driven Monocyte Recruitment to Inflamed Endothelium Under Shear Flow
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EV) hold promising potential for immunomodulation and tissue regeneration, especially for treating ischemia-reperfusion injury (IRI). However, their therapeutic use is hindered by challenges in tissue targeting and incomplete understanding of their functional mechanisms. Upon systemic administration, MSC-EV first encounter IRI-activated endothelium, whose response would determine the nature and extent of subsequent immune cell infiltration and inflammation, with monocytes shaping the type of immune response. Our previous work showed that surface N-glycans are key for MSC-EV interaction with endothelial cells. Here, we investigate the role of N-glycosylation in MSC-EV interaction with TNF-activated endothelial cells and subsequent monocyte rolling and adhesion. Using static and dynamic flow in vitro models, we show that depletion of surface N-glycans specifically targeted MSC-EV to inflamed endothelium. Conversely, while intact MSC-EV inhibited monocyte adhesion and fostered MSC recruitment to endothelial cells, this was lost upon N-glycan depletion. Finally, our results suggest that MSC-EV-mediated modulation of the MCP-1/CCR2 interaction may underlie the reduced monocyte infiltration into inflamed endothelium. These findings highlight the role of N-glycosylation in the immunomodulatory activity of MSC-EV, offering a potential mechanism of action and suggesting that glycoengineered MSC-EV may enhance their therapeutic effectiveness in inflammatory and ischemic conditions., This work was supported in part by grants from MICINN (PID2019-110137RB-I00), Instituto de Salud Carlos III (ISCIII) (ICI20/00135), andit was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). It was further supported by two GEIVEX mobility fellowships awarded to M.C.-S. and M.M.-T. Furthermore, REMAR group is recognized as a consolidated research group by AGAUR (SGR-GRC-00187) and is funded by the ISCIII RICORS program to RICORS2040 (RD24/0004/0005) and CERTERA
(CERT22/00052) funded by the European Union—NextGeneration EU, Mecanismo para la Recuperación y la Resilencia (MRR) M.C.-S and M.F. are supported by grants from ISCIII (FI20/00021 and MS19/00018), co-funded by ERDF/ESF, “Investing in your future”. M.M.-T. was supported by Fondation Pierre Mercier pour la Science. S.G.-G. issupported by the Catalan Health Department (“Departament de Salut”) in receipt of a grant from PERIS-PIF-Salut (SLT017/20/000158). F.E.B. is a researcher from Germans Trias i Pujol Health Science Research Institute, supported by the Health Department of the Catalan Government(Generalitat de Catalunya)., Peer reviewed, Modelo experimental alternativo-NAM, in vitro
DOI: http://hdl.handle.net/10261/437423, https://api.elsevier.com/content/abstract/scopus_id/105040513947
HANDLE: http://hdl.handle.net/10261/437423, https://api.elsevier.com/content/abstract/scopus_id/105040513947